

## IN THE UNITED STATES PATENT &amp; TRADEMARK OFFICE

APPLICANT : Stephen Douglas Barrett, et al. EXAMINER :  
SERIAL NO. : 10/031,037 ART UNIT :  
FILED : January 15, 2002 PAPER NO :  
FOR : METHOD FOR TREATING CHRONIC PAIN USING MEK INHIBITORS

RECEIVED  
JUL 02 2002  
TECH CENTER 1600/2900

Statement as Provided by 37 CFR 1.97(b)

Commissioner for Patents  
Washington, D.C. 20231


Dear Sir:

The Information Disclosure Statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of the first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

It is understood by the Applicants that this paper requires no fee; however, authorization is given to charge any necessary filing fees and any additional fees or credit any overpayment to Deposit Account 23-0455.

Respectfully submitted,

Dated: May 15, 2002

  
Suzanne M. Harvey  
Registration No. 42,640  
Warner-Lambert Company  
2800 Plymouth Road  
Ann Arbor, MI 48105  
Telephone: (734) 622-2658  
Facsimile: (734) 622-1553

+

Approved for use through 10/31/2002. OMB 0651-0081

Approved for use through 10/31/2002. OMB 0651-0051  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete if Known**

(use as many sheets as necessary)

1

of

2

10/031037

Filing Date

January 15, 2002

**First Named Inventor**

Stephen Douglas Barrett, et al

Group Art Unit

Examiner Name

Attorney Docket Number

A0000102-01-SMH

[illegible][illegible]

Examiner  
Signature

Date \_\_\_\_\_

**Considered**

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08B (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449B/PTO</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)				<b>Complete if Known</b>	
				<b>Application Number</b>	10/031037
				<b>Filing Date</b>	January 15, 2002
				<b>First Named Inventor</b>	Stephen Douglas Barrett, et al.
				<b>Group Art Unit</b>	
				<b>Examiner Name</b>	
<b>Sheet</b>	2	<b>of</b>	2	<b>Attorney Docket Number</b>	A0000102-01-SMH

<b>OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS</b>			
<b>Examiner Initials*</b>	<b>Cite No.<sup>1</sup></b>	<b>Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.</b>	<b>T<sup>2</sup></b>
		PCT International Search Report PCT/US00/18345	
		H. BEKEMEIER, et al., "Structure-Activity Relationship in Nonsteroidal Antinflammatory Agents, Including Qsar in Fenamate Derivatives", Agents and Actions Supplements, July 1, 1982, pp 17-34	
		J. V. DUNCIA, et al., "MEK Inhibitors: The Chemistry and Biological Activity of U0126, Its Analogs, and Cyclization Products", Bioorganic & Medicinal Chemistry Letters, 1998, pp 2839-2844, No. 8	
		N. S. DUESBERY, et al., "MEK Waars, a new front in the Battle Against Cancer", Nature Medicine, July 1999, pp 736-737, Vol. 5, No. 7	
		RU-RONG JI, et al., "Nociceptive-specific Activation of ERK in Spinal Neurons Contributes to Pain Hypersensitivity", Nature Neuroscience, December 1999, pp 1114-1119, Vol. 2, No. 12	

<b>Examiner Signature</b>		<b>Date Considered</b>	
-------------------------------	--	----------------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.